|本期目录/Table of Contents|

[1]范文淑,张晓娜,郭伟红 综述,等.糖尿病肾小管病的发病机制及诊治的新进展[J].天津医科大学学报,2022,28(02):226-229.
点击复制

糖尿病肾小管病的发病机制及诊治的新进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
28卷
期数:
2022年02期
页码:
226-229
栏目:
综述
出版日期:
2022-03-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2022)02-0226-04
作者:
范文淑1; 张晓娜2; 郭伟红2 综述; 何庆2 审校
（1. 天津医科大学总医院滨海医院内分泌科，天津 300480；2. 天津医科大学总医院内分泌代谢科，天津 300052）
Author(s):
-
关键词:
糖尿病; 生物标志物; 降糖药物
Keywords:
-
分类号:
R587.2
DOI:
-
文献标志码:
A
摘要:
糖尿病肾小管病（DT）是一个独立的疾病，同时也是糖尿病肾脏病（DKD）重要的一部分。因为DT的病变在DKD的疾病进展中起着重要作用，所以DT的早期诊断和有效治疗显得尤为重要，本文将主要阐述DT的概念、发病机制、诊断和治疗的新进展。
Abstract:
-

参考文献/References:

[1] TANG S，LEUNG J，LAI K N. Diabetic tubulopathy： an emerging entity[J]. Contrib Nephrol，2011，170：124-134.
[2] 柒春芳，陈祖姣，王文健. 糖尿病肾小管病[J]. 中华肾脏病杂志，2020，36（4）：321-326.
[3] HEERSPINK H J，PERKINS B A，FITCHETT D H，et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus：cardiovascular and kidney effects，potential mechanisms，and clinical applications[J]. Circulation，2016，134（10）：752-772.
[4] LI Y，TENG D，SHI X，et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association：national cross sectional study[J]. BMJ，2020，369：m997.
[5] TONNEIJCK L，MUSKIET M H，SMITS M M，et al. Glomerular hyperfiltration in diabetes：mechanisms，clinical significance，and treatment[J]. J Am Soc Nephrol，2017，28（4）：1023-1039.
[6] XIAO L，XU X，ZHANG F，et al. The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1[J]. Redox Biol，2017，11：297-311.
[7] WANG J，YUE X，MENG C，et al. Acute hyperglycemia may induce renal tubular injury through mitophagy inhibition[J]. Front Endocrinol （Lausanne），2020，11：536213.
[8] CHEN Q，SU Y，JU Y，et al. Astragalosides Ⅳprotected the renal tubular epithelial cells from free fatty acids-induced injury by reducing oxidative stress and apoptosis[J]. Biomed Pharmacother，2018，108：679-686.
[9] HAN Y，XU X，TANG C，et al. Reactive oxygen species promote tubular injury in diabetic nephropathy：the role of the mitochondrial ros-txnip-nlrp3 biological axis[J]. Redox Biol，2018，16：32-46.
[10] WANG J Y，YANG J H，XU J，et al. Renal tubular damage may contribute more to acute hyperglycemia induced kidney injury in non-diabetic conscious rats[J]. J Diabetes Complications，2015，29（5）：621-628.
[11] WU N，SHEN H，LIU H，et al. Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis，oxidative stress and pro-inflammatory cytokine expression in vivo[J]. Cardiovasc Diabetol，2016，15（1）：109.
[12] KOGOT-LEVIN A，HINDEN L，RIAHI Y，et al. Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors[J]. Cell Rep，2020，32（4）：107954.
[13] DAS N A，CARPENTER A J，BELENCHIA A，et al. Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression，and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition[J]. Cell Signal，2020，68：109506.
[14] XUE M，SUN H，XU R，et al. GADD45B promotes glucose-induced renal tubular epithelial-mesenchymal transition and apoptosis via the p38 MAPK and JNK signaling pathways[J]. Front Physiol，2020，11：1074.
[15] GLUHOVSCHI C，GLUHOVSCHI G，PETRICA L，et al. Urinary biomarkers in the assessment of early diabetic nephropathy[J]. J Diabetes Res，2016，2016：4626125.
[16] MORESCO R N，SANGOI M B，DE CARVALHO J A，et al. Diabetic nephropathy：traditional to proteomic markers[J]. Clin Chim Acta，2013，421：17-30.
[17] LEE S Y，CHOI M E. Urinary biomarkers for early diabetic nephropathy：beyond albuminuria[J]. Pediatr Nephrol，2015，30（7）：1063-1075.
[18] MISE K，HOSHINO J，UENO T，et al. Prognostic value of tubulointerstitial lesions，urinary N-Acetyl-β-d-Glucosaminidase，and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy[J]. Clin J Am Soc Nephrol，2016，11（4）：593-601.
[19] ARCEO E S，DIZON G A，TIONGCO R. Serum cystatin C as an early marker of nephropathy among type 2 diabetics：a meta-analysis[J]. Diabetes Metab Syndr，2019，13（6）：3093-3097.
[20] CAMPION C G，SANCHEZ-FERRAS O，BATCHU S N. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy[J]. Can J Kidney Health Dis，2017，4：2054358117705371.
[21] PALLET N，CHAUVET S，CHASSé J F，et al. Urinary retinol binding protein is a marker of the extent of interstitial kidney fibrosis[J]. PLoS One，2014，9（1）：e84708.
[22] ZHANG D，YE S，PAN T. The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes[J]. Peer J，2019，7：e7079.
[23] PANDURU N M，SANDHOLM N，FORSBLOM C，et al. Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy： a likely causal link in patients with type 1 diabetes[J]. Diabetes Care，2015，38（6）：1130-1137.
[24] TANASE D M，GOSAV E M，RADU S，et al. The predictive role of the biomarker kidney molecule-1（KIM-1） in acute kidney injury （AKI） Cisplatin-Induced Nephrotoxicity[J]. Int J Mol Sci，2019，20（20）：5238
[25] 中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏疾病防治临床指南[J]. 中华糖尿病杂志，2019，11（1）：15-28.
[26] 张德园，钟兴，潘天荣. 达格列净对血糖控制不佳的2型糖尿病患者肾脏保护作用的研究[J]. 中国糖尿病杂志，2019，27（11）：806-811.
[27] PERKOVIC V，JARDINE M J，NEAL B，et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med，2019，380（24）：2295-2306.
[28] 尹卫芹，许世清，翟敏，等. GLP-1减轻糖基化终末产物对肾小管上皮细胞（HK-2）重吸收功能的影响[J]. 中日友好医院学报，2018，32（3）：159-164.
[29] MARSO S P，BAIN S C，CONSOLI A，et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med，2016，375（19）：1834-1844.
[30] MOSENZON O，LEIBOWITZ G，BHATT D L，et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial[J]. Diabetes Care，2017，40（1）：69-76.
[31] 刘高虹，兰青，张湾，等. 西格列汀对高糖诱导的肾小管上皮细胞凋亡和p38丝裂原活化蛋白激酶通路的影响[J]. 中华糖尿病杂志，2019，11（4）：282-286.

相似文献/References:

[1]王树峰,杨 丽,刘 寅.脂蛋白相关磷脂酶A2与冠心病和2型糖尿病的关系[J].天津医科大学学报,2013,19(06):456.
　WANG Shu-feng,YANG Li,LIU Yin.Relationship between lipoprotein-associated phospholipase A2 and coronary heart disease as well as type 2 diabetes mellitus[J].Journal of Tianjin Medical University,2013,19(02):456.
[2]苏东峰,聂秀玲,孙丽荣.2型糖尿病合并高尿酸血症临床特征及相关危险因素分析[J].天津医科大学学报,2013,19(06):481.
[3]武 鑫,李明珍,孙丽荣.2型糖尿病患者血清γ-谷氨酰转移酶与胰岛β细胞功能的关系[J].天津医科大学学报,2014,20(02):147.
　WU Xin,LI Ming-zhen,SUN Li-rong.Association of serum gamma-glutamyltransferase with islet β cell function in type 2 diabetic patients[J].Journal of Tianjin Medical University,2014,20(02):147.
[4]刘 芳,李明珍,孙丽荣.住院2型糖尿病患者睡眠质量与血糖及并发症的关系[J].天津医科大学学报,2014,20(03):213.
　LIU Fang,LI Ming-zhen,SUN Li-rong.Relationship between sleep quality and glucose level as well as diabetic complications in hospital patients with type 2 diabetes mellitus[J].Journal of Tianjin Medical University,2014,20(02):213.
[5]李凤英,朱铁虹.中年男性2型糖尿病患者促甲状腺激素与尿钙/肌酐比值的相关性研究[J].天津医科大学学报,2014,20(05):389.
　LI Feng-ying,ZHU Tie-hong.Relationship between thyroid stimulating hormone and urinary calcium/creatinine excretion in middle-aged man with type 2 diabetes[J].Journal of Tianjin Medical University,2014,20(02):389.
[6]谭艳萍,吴校伟,刘 寅,等. 冠心病合并糖尿病患者药物涂层支架术后观察[J].天津医科大学学报,2014,20(05):414.
[7]陈河清,郭秀梅,金力里.2型糖尿病患者牙周病与糖尿病肾病的相关性分析[J].天津医科大学学报,2014,20(06):469.
　CHEN He-qing,GUO Xiu-mei,JIN Li-li. Correlation between diabetic nephropathy and periodontal disease[J].Journal of Tianjin Medical University,2014,20(02):469.
[8]马 静,赵立华,谢 云.血浆纤维蛋白原与糖尿病肾病的相关性研究[J].天津医科大学学报,2015,21(03):60.
　Ma Jing,ZHAO Li-hua,XIE Yun.Relationship between plasma fibrinogen concentration and diabetic nephropathy [J].Journal of Tianjin Medical University,2015,21(02):60.
[9]马 静,赵立华,谢 云. 血浆纤维蛋白原与糖尿病肾病的相关性研究[J].天津医科大学学报,2015,21(01):60.
　MA Jing,ZHAO Li-hua,XIE Yun.Relationship between plasma fibrinogen concentration and diabetic nephropathy[J].Journal of Tianjin Medical University,2015,21(02):60.
[10]李 冰,冯 凭.罗格列酮干预糖尿病大鼠脂肪组织CMKLR1及Chemerin基因表达[J].天津医科大学学报,2015,21(06):484.
　LI Bing,FENG Ping.Effect of rosiglitazone on the expression of CMKLR1 and Chemerin mRNA in the adipose tissue of diabetic rat[J].Journal of Tianjin Medical University,2015,21(02):484.

备注/Memo

备注/Memo:
基金项目 国家自然科学青年基金（81700720），天津市卫生健康委员会科技项目（ZC20210，RC20126）
作者简介 范文淑（1991-），女，主治医师，学士，研究方向： 糖尿病肾小管病；通信作者：何庆，E-mail:hech69@163.com。
更新日期/Last Update: 2022-03-20